Hamps Bio IPO Subscribed Over 1000 Times So Far On Final Day; Check GMP, Subscription Status And More

The initial share sale of Hamps Bio Ltd., a company engaged in the marketing and distribution of pharmaceutical products, opened for bidding last week. The SME IPO was booked over 10 times on the opening day on Dec. 13.

Hamps Bio IPO has been booked over 1000 times so far on the final day on Tuesday.

The grey market premium (GMP) of Hamps Bio IPO was Rs 51 on December 17, climbing from Rs 35 when the issue opened for subscription on Friday. The GMP trends have shown an upward trend since the announcement of the IPO price band.

The Rs 6.22-crore Hamps Bio IPO (initial public offering) is an entirely fresh issue of 12.2 lakh shares. Investors who want to subscribe to the Hamps Bio IPO must check these details before bidding for the issue:

Hamps Bio IPO price band has been fixed at Rs 51 per share, making it a fixed price issue. Retail investors must buy at least 2,000 shares in one lot, taking the minimum investment amount to Rs 1,02,000.

Bigshare Services Pvt. has been appointed as registrar for the Hamps Bio IPO. Marwadi Chandarana Intermediaries Brokers Pvt. is acting as the book-running lead manager of the issue and Pure Broking is its market maker.

The IPO has been subscribed 1,003.29 times as of 3:50 p.m. on Tuesday.

• Non-Institutional Buyers: 750.33 times

• Retail Investors: 1,242.55 times

Subscription status will be updated at regular intervals.

Hamps Bio IPO GMP (grey market premium) was Rs 51 as of 1:53 p.m. on Tuesday, as per InvestorGain. This projects a potential listing gain of 100%, with the debut price of the Hamps Bio stock being Rs 102 per share at the upper end of the price band.

Note: GMP or grey market price is not an official price quote for the stock and is based on speculation.

Share allotment will be done on December 18. Credit of Hamps Bio shares into the demat account of successful bidders will be done on December 19 along with initiation of refunds to non-allottees.

Shares of Hamps Bio Ltd. are expected to be listed on the BSE SME on December 20.

Hamps Bio Ltd. distributes pharmaceutical products, including tablets, syrups, capsules, injectables, oil and nutritional supplements via a network of over 50 distributors and e-commerce platforms. The platforms include Amazon (US, Canada, EU), Flipkart, and Jio Mart. 

The pharma products are sold in eight states and Union Territories across India. On the other hand, the freeze-dried and frozen products are distributed in six countries as well as 22 states and UTs in India.

Hamps Bio Ltd. will use the net proceeds from the IPO to buy machines and a plant for its FMCG division, as well as increase the brand's visibility and awareness. Further, some of the proceeds will also be used for general corporate purposes.

As of the period ended October 31, the company's revenue from operations was Rs 4.26 crore, while its net profit stood at Rs 34.08 lakh. In FY24, Hamps Bio Ltd. reported a revenue of Rs 6.47 crore and a net profit of Rs 50.07 lakh.

Disclaimer: Investments in initial public offerings are subject to market risks. Please consult with financial advisors and read the red herring prospectus thoroughly before placing bids.